MedTrace Logo

Evaluation of Glycemic Control in Adults With Type 1 Diabetes When Switching to Insulin Degludec

NCT05434559 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 475

Last updated 2022-12-21

No results posted yet for this study

Summary

Retrospective multicenter study analyzing data gathered from medical records and diabetes management platforms to assess the effect of using Insulin Degludec (Tresiba®) on measures of diabetes control.

People with type 1 diabetes who switched to Insulin Degludec from another basal insulin between 1/5/2019 and 1/6/2021 will be included.

Glycemic control from 12 months before the switch to Insulin Degludec will be compared to glycemic control of the 12 months after the switch.

Conditions

Interventions

DRUG

Insulin Degludec

Switch during standard routine care to Insulin Degludec.

Sponsors & Collaborators

  • University Hospital, Antwerp

    collaborator OTHER

  • prof dr Pieter Gillard

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-20
Primary Completion
2022-10-31
Completion
2022-10-31
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05434559 on ClinicalTrials.gov